DNMT3A and kidney disorder: In line with this, the newly developed clonal hematopoiesis risk score, which stratifies the risk of CHIP progression to myeloid cancer and of developing CHIP-associated comorbidities including cardiovascular and kidney disease, accords more points for non-DNMT3A-CHIP compared to DNMT3A-CHIP38.